The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.
* Assignment: Each study subject will serve as their own control. The order of kisspeptin doses will be randomized within each set/exposure. * Delivery of Interventions: * Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories. Subjects will also wear a gonadotropin releasing hormone (GnRH) pump prior to the inpatient study visit. * On the day of the inpatient study, the subjects will * Undergo q10 min blood sampling for 6 hours, * Receive kisspeptin intravenous (IV) boluses from hour 6 to hour 44 (20 boluses total), * Undergo q10 min blood samplings for another 6 hours, * Receive a single GnRH IV bolus at hour 51.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
18
20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
1 intravenous dose of GnRH
Massachusetts General Hospital
Boston, Massachusetts, United States
Average change in luteinizing hormone (LH) pulse amplitude in response to kisspeptin
Change in LH amplitude before, during and after kisspeptin administration
Time frame: 52 hours
Average change in LH pulse frequency in response to kisspeptin
Change in LH frequency before and after kisspeptin administration
Time frame: 52 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.